EnsoData, Parachute Announce Partnership

MADISON, Wisconsin—EnsoData and Parachute Health announce a partnership to expedite care for newly diagnosed sleep disorders like obstructive sleep apnea (OSA) by simplifying the sleep care workflow from diagnostics through therapy prescription ordering. The two organizations will collaborate to create a seamless handoff from a physician-signed sleep report directly through to durable medical equipment suppliers (DME) using Parachute Health to ensure patients receive access to therapy and help to improve sleep health more quickly.

This partnership aims to directly address the OSA epidemic plaguing patients in the U.S. and around the globe. OSA is an immensely prevalent condition impacting approximately 39 million Americans, yet it is estimated that 80% to 90% of cases are still undiagnosed today. Even when patients are diagnosed with OSA, only 50% of patients actually receive the appropriate therapy to address and treat the condition.

Together, EnsoData and Parachute Health announce their partnership and integration to introduce an efficient, collaborative workflow that ensures patients are both diagnosed and then also receive treatment for sleep apnea more quickly, addressing both the severity of the OSA epidemic and the related workflow challenges in the sleep care continuum.

“We’re excited to partner with Parachute Health to better serve patients, sleep physicians and DME providers working from a footprint spanning thousands of physicians and major DMEs,” said Justin Mortara, EnsoData president and CEO. “By partnering together, we’re setting ourselves up to support a high volume of patients immediately, with the ability to truly expand the overall impact we can have on patient lives and sleep medicine.”

The Parachute Platform is the largest integrated DME marketplace and enables any supplier and clinician to join, including the more than 220,000 clinicians on Parachute today. The integration with Parachute Health offers sleep labs a way to extend the efficiencies they have gained in diagnosing patients with EnsoSleep to a simple ordering workflow in Parachute. The ​​platform automatically populates order details from the patient sleep study, improving the accuracy of prescriptions, eliminating duplicate data entry and allowing physicians to track patients from their original sleep tests all the way through their prescription fulfillment.

“At Parachute Health, our mission is to give all patients a ‘soft landing,’ with the life-saving products and services they need. By streamlining CPAP ordering at the point of care, we have dramatically improved both the clinician and patient experience,” said David Gelbard, Parachute Health founder and CEO. “This partnership with EnsoData is an exciting evolution in a series of Parachute partnerships that expand and enhance the Parachute Network and make Parachute Health the industry-leading ePrescribing platform for DME.”

EnsoData and Parachute Health are actively working with early joint customers and expect the integration to be widely available in 2024, paving the way to ensure patients do not fall through the cracks in the care pathway, leading to better patient sleep health, longer lifespans and better population health for our society at large.